Request Appointment
619 19th St SBirmingham, AL 35233
Overview of Dr. Akce
Dr. Mehmet Akce is an oncologist in Birmingham, AL and is affiliated with The University of Alabama at Birmingham. He received his medical degree from Marmara University Faculty of Medicine and has been in practice 8 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in gallbladder cancer, gastric cancer, pancreatic cancer, chemotherapy, and hepatobiliary cancer.
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2014 - 2017
Trinity Health Ann Arbor HospitalChief Residency, Internal Medicine, 2013 - 2014- Trinity Health Ann Arbor HospitalResidency, Internal Medicine, 2010 - 2013
Marmara Univ- Fac MedClass of 2009
Certifications & Licensure
GA State Medical License 2017 - 2026
AL State Medical License 2022 - 2025
MI State Medical License 2010 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer Start of enrollment: 2019 Jan 15
- A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Start of enrollment: 2023 Jan 19
Roles: Contact, Principal Investigator
- Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer Start of enrollment: 2023 Jul 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.Al B Benson 3rd, Michael I D'Angelica, Thomas Abrams, Aijaz Ahmed, Mehmet Akce
Journal of the National Comprehensive Cancer Network. 2025-09-01 - HER2 alterations across solid tumors: implications for comprehensive testing.Ahmed Ismail, Chimay Jani, Nusrat Jahan, Malla Midhun, Arnab Basu
The Oncologist. 2025-09-01 - Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A single cell ...Ganji Purnachandra Nagaraju, Madhu Sudhana Saddala, Sujith Sarvesh, Dhana Sekhar Reddy Bandi, Ateeq M Khaliq
Cancer Letters. 2025-08-10
Journal Articles
- The Potential of CAR T Cell Therapy in Pancreatic CancerMehmet Akce, Mohammad Y Zaidi, Edmund K Waller, Frontiers in Neurology
Lectures
- The impact of inflammatory biomarkers, BMI, and sarcopenia on survival in advanced hepatocellular carcinoma treated with immunotherapy.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Impact of high-risk features for stage II adenocarcinoma of the appendix.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies: Results of the dose-escalation phase.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Press Mentions
Advancing Health Through DiscoveryJuly 22nd, 2025- Hepatocellular Carcinoma, Novel Therapies on the HorizonJuly 22nd, 2021
Grant Support
- Preoperative immunotherapy in Hepatocellular CarcinomaEMORY UNIVERSITY2023–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
